AZN - Lexicon initiated at buy at Jefferies on uptake of heart failure candidate sotagliflozin

"We do think the [heart failure with preserved ejection fraction (HFpEF)] subpopulation is a relatively attractive opportunity [vs heart failure with reduced ejection fraction (HFrEF)], but having to compete against AstraZeneca's ( AZN ) Farxiga and Eli Lilly's ( LLY ) Jardiance (established SGLT2s) could still be challenging," Tsai wrote.

"Also, KOLs have gained years of experience with other HF drugs (including SGLT2s), so they may be reluctant to switch patients over to sotagliflozin."

Read why Seeking Alpha contributor Stephen Simpson argues that Lexicon ( LXRX ) is a buy.